Phosphodiesterase-IN-5

Phosphodiesterase-IN-5 is a potent, orally active and selective phosphodiesterase 10A (PDE10A) inhibitor with an IC50 of 6.2 nM. Phosphodiesterase-IN-5 shows >1612-fold selectivity over other PDEs. Phosphodiesterase-IN-5 exhibits potent antifibrotic efficacy in a Bleomycin (BLM) (HY-108345) -induced murine model of pulmonary fibrosis (PF) by blocking myofibroblast differentiation via the cAMP/PKA/CREB signaling pathway. Phosphodiesterase-IN-5 can be used for the research of PF[1].

Product Specifications

UNSPSC

12352005

Target

Collagen; Interleukin Related; Phosphodiesterase (PDE) ; PKA; TNF Receptor

Related Pathways

Apoptosis; Cytoskeleton; Immunology/Inflammation; Metabolic Enzyme/Protease; Stem Cell/Wnt; TGF-beta/Smad

Field of Research

Inflammation/Immunology

Smiles

O=C(C1=C(C2CN(C3=NC(C)=C4C=CC=CC4=N3)C2)N=C5C=CC(F)=CN51)N(C6)CCNC76CC7

Molecular Formula

C26H26FN7O

Molecular Weight

471.53

References & Citations

[1]Zhang F, et al. Structure-Based Optimization of Imidazopyridine Derivatives as Selective and Orally Bioavailable Phosphodiesterase 10A Inhibitors with Reduced Blood-Brain Barrier Penetration for the Treatment of Idiopathic Pulmonary Fibrosis. J Med Chem. 2025;68 (23) :25290-25306.